British Columbia Protocol Compares Take-Home Opioid Agonist Dosing Against Daily Supervision
British Columbia’s opioid crisis has pushed opioid agonist treatment into a narrower clinical dilemma: how to keep people engaged in care without making treatment itself a burden. This protocol takes aim at that question by comparing take-home dosing schedules for opioid agonist treatment against continuous daily dosing in a population-based cohort across the province. The focus is practical and immediate. If fewer pharmacy visits improve retention without worsening safety, then the schedule itself becomes part of the therapy.
The study is designed as a target trial emulation, a framework built to mirror a randomized trial as closely as possible using observational data. Investigators will follow adults who started methadone or buprenorphine/naloxone between 1 January 2010 and 31 December 2022 in British Columbia. Eligibility excludes people who were incarcerated or pregnant at baseline, along with those with a history of cancer or palliative care. The cohort is drawn from nine linked health administrative databases, giving the analysis the breadth needed to capture treatment patterns across routine care rather than a narrow trial setting.
Why Dosing Frequency May Change Retention in Opioid Agonist Treatment
Daily observed dosing reduces diversion risk, but it also creates a repeated logistical demand. Patients must travel, wait, coordinate work or caregiving, and return again the next day. For some, that repetition becomes a barrier large enough to fracture engagement. Take-home doses reduce that burden and may strengthen adherence by making treatment more compatible with ordinary life.
In the fentanyl era, that trade-off has become more consequential. The illicit drug supply has grown more toxic, and treatment continuity carries added weight when interruptions can quickly translate into overdose risk. The biological and behavioral logic is straightforward: more flexible access may support persistence in care, while overly restrictive dispensing can push people away from treatment before stabilization occurs.
This protocol compares three take-home categories — 2 to 5 days, 6 days, and more than 6 days — with continuous daily dosing. The design does not assume that more flexibility is always better. Instead, it asks whether differing schedules change the odds of OAT discontinuation and all-cause mortality on treatment, two outcomes that sit at the center of real-world addiction care.
Emulating a Trial Without Randomizing Patients
Randomized trials are difficult in this setting because dosing schedules are shaped by clinical judgment, patient stability, housing, substance use patterns, and local policy. A person given six take-home doses is not interchangeable with someone attending daily. Confounding by indication is built into the care pathway.
To address that problem, the investigators plan a causal per-protocol analysis with longitudinal matching and inverse probability of censoring weighting. Those methods are meant to adjust for both time-fixed and time-varying confounding, helping isolate the effect of the dosing schedule itself rather than the characteristics of the people who received it. A series of sensitivity analyses will test how robust the findings remain under alternate assumptions.
The statistical strategy matters because take-home prescribing can change over time. A patient may begin with daily supervision, earn more flexibility, and later return to closer monitoring if stability changes. Longitudinal methods are built to follow those shifts rather than freeze exposure at baseline. In a treatment environment as dynamic as opioid agonist care, that flexibility in the analytic plan is not decorative; it is essential.
The Outcomes Focus on Retention and Death on Treatment
The protocol’s primary endpoints are clinically direct. Treatment discontinuation captures whether people remain connected to care, while death on treatment addresses safety in a population at high risk for overdose and other causes of mortality. Those outcomes reflect the two forces constantly in tension in opioid agonist prescribing: access and oversight.
A schedule that improves retention without increasing mortality would support broader use of take-home dosing. A schedule that appears convenient but weakens continuity, or one that proves safer but drives dropout, would force a different conversation. Either way, the comparison addresses a gap in the evidence base that has become more visible as fentanyl has changed the risk environment for people receiving opioid agonist therapy.
The protocol does not claim results. It lays out how those results will be estimated once the linked provincial data are analyzed, and it does so at a scale that should capture practice as it occurs across British Columbia rather than in a single clinic or selected subgroup.
A Province-Wide Data Linkage Anchored in Routine Care
Nine linked administrative databases will support the analysis, allowing investigators to trace medication dispensing, clinical encounters, and survival outcomes across the province. Population-level linkage strengthens the study’s ability to reflect routine care, where patients move between prescribers, pharmacies, and services. It also reduces dependence on self-report, which can be fragile in addiction research.
The study spans more than a decade, from 2010 through 2022, a period long enough to capture changes in prescribing practice, the rise of fentanyl in the illicit supply, and shifting clinical responses to overdose risk. That time span should also allow the team to examine whether the comparative value of take-home schedules changed as the treatment environment changed.
One sentence captures the central tension: more flexible dosing may keep people in treatment longer, but less supervision can also expose weaknesses in how stability is judged and monitored.
Ethics Review, Dissemination, and Guideline Relevance
The protocol, cohort creation, and analysis plan were classified and approved as a quality improvement initiative by Providence Health Care Research Ethics Board and the Simon Fraser University Office of Research Ethics. Findings will be shared with local advocacy groups, decision-makers, and developers of national and international clinical guidelines, and they will be presented at conferences and published in peer-reviewed journals.
The audience for the eventual results is obvious. Program leaders want evidence that can guide dispensing policy. Clinicians need a clearer sense of which take-home schedules preserve engagement without creating avoidable risk. People receiving opioid agonist treatment need care models that recognize both the pharmacology of withdrawal suppression and the lived burden of repeated clinic attendance.
Until the comparative results are available, the protocol remains exactly what it says it is: a structured attempt to answer a high-stakes clinical question with the best available population data. The next step is not conceptual; it is empirical, and it will depend on whether the province-wide data can show a measurable difference between daily supervision and progressively more flexible take-home schedules.